Innate Pharma SA — FY 2022 Form 20-F
Period and basis: Annual report for the fiscal year ended December 31, 2022, filed April 5, 2023; this is not a stand-alone Q4 report, and separate quarterly financial results are not provided. Audited consolidated statements are in euros under IFRS as issued by the IASB.
Business context
Innate Pharma is a clinical-stage oncology biotechnology company developing immunotherapies, including proprietary lacutamab and ANKET programs and partnered candidates with AstraZeneca and Sanofi. The company has no manufacturing capabilities and relies on partners and external suppliers. It had no material product-sales revenue in 2022; income primarily came from collaboration agreements and French research tax credits.
Key financial metrics
| Metric (€ millions, except per-share data) | 2022 | 2021 |
|---|---|---|
| Revenue and other income | 57.7 | 24.7 |
| Collaboration and licensing revenue | 49.6 | 12.1 |
| Research tax credits and other research funding | 8.0 | 12.6 |
| Research and development expense | 51.7 | 47.0 |
| General and administrative expense | 22.4 | 25.5 |
| Impairment of intangible assets | 41.0 | — |
| Operating loss | (57.4) | (47.8) |
| Net financial income (loss) | (0.5) | 2.3 |
| Net loss, continuing operations | (58.0) | (45.5) |
| Net loss, including discontinued operations | (58.1) | (52.8) |
| Basic and diluted loss per share | €(0.73) | €(0.66) |
| Cash and cash equivalents | 84.2 | 103.8 |
| Cash, cash equivalents and short-term investments | 101.5 | 119.8 |
| Cash, cash equivalents, short-term investments and non-current financial assets | 136.6 | 159.7 |
| Net cash used in operating activities | (19.2) | (58.5) |
| Total assets | 207.9 | 267.5 |
| Total shareholders’ equity | 54.2 | 107.4 |
| Financial liabilities, current and non-current | 42.3 | 44.3 |
Margins are not a useful measure of commercial performance for this development-stage company; no product-sales base is reported for continuing operations. The 2022 operating loss includes the €41.0 million avdoralimab impairment. The balance-sheet financial-liability figure includes lease liabilities; the filing separately reports total financial debt and defined-benefit obligations of €44.8 million.
Material changes versus 2021
- Revenue and other income rose €33.0 million, mainly from a €50 million AstraZeneca monalizumab milestone linked to the first patient in PACIFIC-9, a €5 million IPH5201 milestone, and recognition of a €17.4 million upfront payment after AstraZeneca declined options on four preclinical programs. These items are not necessarily recurring.
- R&D expense increased 9.9% to €51.7 million, reflecting higher preclinical and indirect costs; general and administrative expense fell 12.1% to €22.4 million.
- Operating loss widened by €9.6 million, principally because of the avdoralimab impairment and increased R&D spending. Total net loss increased €5.3 million.
- Operating cash outflow improved by €39.3 million, chiefly because of collaboration milestone receipts and early repayment of the 2021 research tax credit. Management states that, excluding specified receipts and payments, operating cash use increased by €10.4 million, reflecting higher development and monalizumab co-funding costs.
- Cash, cash equivalents and short-term investments declined €18.4 million. The €28.7 million of state-guaranteed loans received in 2021 were extended in 2022, with 2023 principal-payment grace and amortization beginning in 2024.
Outlook, risks and unusual items
- Funding: Management says available resources and operating cash flow are expected to fund operations for the next two years in one section, but the liquidity discussion says existing liquidity is expected to fund operations for the next twelve months. The filing also says additional funding will be needed to complete development and potential commercialization. These runway statements should be reconciled; milestone timing and R&D spending are uncertain.
- Clinical and portfolio risk: AstraZeneca discontinued the Phase 3 INTERLINK-1 monalizumab trial after a planned futility analysis failed to meet its predefined efficacy threshold; no new safety finding was reported. PACIFIC-9 remains under study. The sponsor stopped the avdoralimab bullous pemphigoid Phase 2 study, leading to a full €41 million impairment. Lacutamab remains in Phase 2 for lymphoma; the company reported interim activity but said more follow-up was needed.
- Partner dependence: Collaboration and license agreements are expected to provide a large share of revenue. Potential milestone and royalty amounts—including up to approximately $3.6 billion across existing and option agreements—are contingent and not assured. Sanofi’s B7-H3 ANKET agreement became effective in January 2023; its €25 million upfront payment was received in March 2023, after year-end, and up to €1.35 billion in milestones plus royalties is contingent on future events.
- Tax and contingencies: A €1.27 million provision was recorded following a French tax review of 2018–2020 research tax credits and related matters; tax authorities’ March 2023 proposal confirmed the provision for undisputed adjustments. The company also disclosed €8.8 million of non-cancellable supplier commitments, mainly CRO and CMO work, and €15.2 million of financial collateral pledged against its headquarters-related loan. Management reported no legal proceeding expected to have a material adverse effect.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2022 because of a material weakness involving financial-statement classification and presentation and recording third-party services in the correct period. Identified 2022 errors were corrected, but remediation was not yet established as effective. The auditor gave an unqualified opinion on the IFRS financial statements but did not attest to internal-control effectiveness.
- Other risks: Clinical-trial efficacy, safety, enrollment and manufacturing supply; regulatory approval and reimbursement; reliance on AstraZeneca, Sanofi and third-party manufacturers; potential need for additional capital; foreign-exchange exposure without hedging; and dilution from equity awards and future financing.
Investor verification priorities
- Reconcile the stated 12-month versus two-year cash runway and test it against operating burn, planned trials, collaboration cost-sharing and expected tax-credit receipts.
- Track PACIFIC-9 and lacutamab trial progress and confirm the consequences of INTERLINK-1’s discontinuation and the avdoralimab write-off for future milestone income.
- Verify the timing, accounting and cash impact of the €25 million Sanofi upfront payment received in March 2023, and distinguish contingent milestones from committed funding.
- Review the €1.27 million tax provision, future French research-tax-credit eligibility and collection timing, and the pledged-collateral and minimum-cash covenant on the Société Générale loan.
- Assess whether the company’s remediation of its material weakness has operated effectively and whether additional reporting errors arise.
- Check the share-count disclosures: the cover reports 79,542,627 ordinary shares at year-end, while the financial-statement share-capital and share-movement disclosures report differing totals. Also assess potential dilution from outstanding equity awards.